arrow
Y

Yang Liang

中山大学肿瘤防治中心
H指数:20
被引数:3,194

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Venetoclax plus azacitidine, low-dose cytarabine, aclarubicin, and G-CSF (VA-CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single-arm Phase II clinical trial

维奈克拉联合阿扎胞苷、低剂量阿糖胞苷、阿克拉霉素和G-CSF(VA-CAG方案)用于新诊断年轻急性髓系白血病患者的治疗:一项前瞻性、多中心、单臂II期临床试验

2026-08-120
OAAI
A Visual Nomogram Survival Prediction Model in Acquired Immune Deficiency Syndrome (AIDS)-Related Diffuse Large B-Cell Lymphoma

一种用于获得性免疫缺陷综合征(AIDS)相关弥漫性大B细胞淋巴瘤的视觉诺莫图生存预测模型

2025-04-210
PRE
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging study
2025-02-200
OAAI
Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Lisaftoclax (APG-2575), 一种新型BCL-2抑制剂,与阿扎胞苷联合治疗骨髓增生异常综合征(MDS)患者。

BLOOD
IF23.1
2024-11-050
PRE
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial

Aponermin或安慰剂联合沙利度胺和地塞米松治疗复发或难治性多发性骨髓瘤 (CPT-MM301): 一项随机,双盲,安慰剂对照的3期试验

2023-10-1413
OAAI